Novartis' Fabhalta is first FDA-approved therapy for rare disease C3G

Submitted by admin on March 21, 2025 - 11:19am

Source:

Pharmaphorum

News Tags:

Novartis

FDA

Fabhalta

C3 glomerulopathy

Headline:

Novartis' Fabhalta is first FDA-approved therapy for rare disease C3G

snippet:

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Search form

You are here

Novartis' Fabhalta is first FDA-approved therapy for rare disease C3G

Novartis' Fabhalta is first FDA-approved therapy for rare disease C3G